Item 5.07. Submission of Matters to a Vote of Security Holders.

Capricor Therapeutics, Inc. (the "Company") held its 2020 Annual Meeting of Stockholders (the "Annual Meeting") on June 5, 2020 at the Company's principal executive offices located at 8840 Wilshire Blvd., Beverly Hills, California 90211. At the Annual Meeting, the Company's stockholders were asked to vote upon the following five proposals, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 17, 2020:





    1.   The election of six nominees to the Company's Board of Directors to
         serve until the 2021 annual meeting of stockholders. The nominees for
         election were Frank Litvack, M.D., Linda Marbán, Ph.D., David B. Musket,
         George W. Dunbar, Jr., Louis Manzo and Earl M. (Duke) Collier, Jr.;

    2.   The ratification of the appointment by the Audit Committee of the
         Company's Board of Directors of Rose, Snyder & Jacobs LLP as the
         Company's independent registered public accounting firm for the fiscal
         year ending December 31, 2020;

    3.   To approve the adoption of the Capricor Therapeutics 2020 Equity
         Incentive Plan;

    4.   To approve, by non-binding advisory vote, the resolution approving named
         executive officer compensation; and

    5.   To approve, by non-binding advisory vote, the frequency of future
         non-binding advisory votes on resolutions approving named executive
         officer compensation.

The final results of the matters voted on at the Annual Meeting, based on the presence in person or by proxy of holders of record of 7,778,818 shares of the 12,464,006 shares of the Company's common stock entitled to vote, were as follows:





     1.   Each of Dr. Litvack, Dr. Marbán, and Messrs. Musket, Dunbar, Manzo, and
          Collier were elected as directors of the Company to serve until the 2021
          annual meeting of stockholders, and until his or her successor is
          elected, or until his or her earlier death, resignation or removal, as
          follows:




                                   FOR    WITHHELD BROKER NON-VOTES
    Frank Litvack, M.D.         1,994,731  35,877     5,748,210
    Linda Marbán, Ph.D.         2,004,415  26,193     5,748,210
    David B. Musket             1,856,651 173,957     5,748,210
    George W. Dunbar, Jr.       1,858,096 172,512     5,748,210
    Louis Manzo                 1,857,775 172,833     5,748,210
    Earl M. (Duke) Collier, Jr. 2,010,868  19,740     5,748,210




     2.   The appointment by the Audit Committee of the Company's Board of
          Directors of Rose, Snyder & Jacobs LLP as the Company's independent
          registered public accounting firm for the fiscal year ending December
          31, 2020 was ratified as follows:




       FOR    AGAINST ABSTAIN BROKER NON-VOTES
    7,616,245 29,998  132,575        0




     3.   The adoption of the Capricor Therapeutics 2020 Equity Incentive Plan was
          approved as follows:




       FOR    AGAINST ABSTAIN BROKER NON-VOTES
    1,766,874 213,632 50,102     5,748,210




     4.   The compensation of the Company's named executive officers was approved,
          on a non-binding advisory basis, as follows:




       FOR    AGAINST ABSTAIN BROKER NON-VOTES
    1,796,613 188,929 45,006     5,748,210




     5.   The preferred frequency, on a non-binding advisory basis, of future
          non-binding advisory votes to approve the compensation of the Company's
          named executive offices was "1 Year" as follows:




  THREE YEARS TWO YEARS ONE YEAR  ABSTAIN BROKER NON-VOTES
    347,621    74,466   1,570,885 37,636     5,748,210

© Edgar Online, source Glimpses